TH62247A - - Google Patents

Info

Publication number
TH62247A
TH62247A TH1004097A TH0001004097A TH62247A TH 62247 A TH62247 A TH 62247A TH 1004097 A TH1004097 A TH 1004097A TH 0001004097 A TH0001004097 A TH 0001004097A TH 62247 A TH62247 A TH 62247A
Authority
TH
Thailand
Prior art keywords
drug
dose
increasing
tolerate
formulation
Prior art date
Application number
TH1004097A
Other languages
English (en)
Thai (th)
Original Assignee
นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก
Filing date
Publication date
Application filed by นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก filed Critical นายจักรพรรดิ์ มงคลสิทธิ์ นางสาวปรับโยชน์ ศรีกิจจาภรณ์ นายบุญมา เตชะวณิช นายต่อพงศ์ โทณะวณิก
Publication of TH62247A publication Critical patent/TH62247A/th

Links

TH1004097A 2000-10-25 TH62247A (es)

Publications (1)

Publication Number Publication Date
TH62247A true TH62247A (es) 2004-06-03

Family

ID=

Similar Documents

Publication Publication Date Title
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2006089843A3 (fr) Forme medicamenteuse orale microparticulaire anti-mesusage
MY143795A (en) Tetrahydropyridoindole derivatives
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
MXPA03010679A (es) Una composicion para acelerar la cicatrizacion de fractura osea.
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration